Clinical Trial Update: Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 clinical trial update evaluating the safety and feasibility of using Exablate to disrupt the blood-brain barrier in individuals with mild cognitiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Exablate Blood-Brain Barrier Disruption device
• Monoclonal antibody therapy (unspecified)

Snippet

Sponsor: Ali Rezai | Conditions: Mild Cognitive Impairment, Alzheimer Disease 1 | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING